Table 2.
Immune‐related genomic signatures included in the study
| Signature/author/year | Outcome | Number of genes in signature | Patients with the signature classified asa | Reference | |||
|---|---|---|---|---|---|---|---|
| Original | Available (%) | Poor (%) | Uncertainty (%) | Good (%) | |||
| 95‐gene STAT1‐related immune metagenes; Desmedt et al; 2008. | NA | 95 | 69 (72.6) | 48 (6.8) | 411 (57.8) | 252 (35.4) | 17 |
| B‐cell/IL‐8 metagenes; Rody et al; 2011. | DFS | 216 | 186 (86.1) | 205 (28.8) | 409 (57.5) | 97 (13.7) | 20 |
| Immune cells metagenes; Nagalla et al; 2013. | DMFS | 70 | 52 (74.3) | 61 (8.6) | 393 (55.3) | 257 (36.1) | 19 |
| HER2‐derived prognostic predictor enriched in immune genes; Staaf et al; 2010 | OS DMFS | 14 | 13 (92.9) | 15 (2.1) | 668 (94.0) | 28 (3.9) | 22 |
| 28‐kinase metagenes associated with immune response; Sabatier et al; 2011. | DFS | 368 | 275 (74.7) | 286 (40.2) | 163 (22.9) | 262 (36.8) | 21 |
DFS, disease‐free survival; DMFS, distant metastasis‐free survival; OS: overall survival.
a
Samples were classified as presence, absence, or uncertainty by respective published genomic signatures based on prediction result (false discover rate [FDR] < 0.05) of nearest template prediction (NTP).